GMAB Stock: Price, Earnings History and SEC Filings
Genmab A/S (GMAB) last traded at $57.06, up 1.01% on the latest session and up 59.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.54 against an analyst estimate of $0.37, a beat of 45.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
GMAB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.54 | $0.37 | +45.95% |
| Mar 2026 | May 7, 2026 | $0.15 | $0.15 | +0.00% |
| Dec 2025 | Feb 17, 2026 | $0.05 | $0.46 | -89.13% |
| Sep 2025 | Nov 6, 2025 | $0.65 | $0.48 | +35.42% |
GMAB beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for GMAB
Insider filing activity
GMAB insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
GMAB news
- Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?Oct 29, 2026 · finance.yahoo.com
- Genmab’s bispecific halves risk of death in first-line HNSCCOct 29, 2026 · clinicaltrialsarena.com
- Genmab soars to record highs after cancer drug succeeds in key trialOct 29, 2026 · biopharmadive.com
- Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?Oct 29, 2026 · stocktwits.com
- Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer LaunchesOct 28, 2026 · marketbeat.com
- Genmab Stock Surges to Record High After Stunning Cancer Drug ResultsOct 28, 2026 · finance.yahoo.com
- Genmab Stock Hits 52-Week High - Here's WhyOct 28, 2026 · finance.yahoo.com
- Top Midday GainersOct 28, 2026 · finance.yahoo.com
About Genmab A/S
Genmab A/S (GMAB) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations.